{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:46:36Z","timestamp":1790837196297,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.clgc.2022.03.006","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T20:55:22Z","timestamp":1647032122000},"page":"390.e1-390.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Axitinib Trough Concentration and its Influence on the Efficacy and Toxicity of Second-line Renal Cell Carcinoma Treatment"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5159-9410","authenticated-orcid":false,"given":"Zuzanna","family":"Synowiec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Soba\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Synowiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Te\u017cyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Tomczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jab\u0142ecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2022.03.006_bib0001","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","article-title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2022.03.006_bib0002","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.03.006_bib0003","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.03.006_bib0004","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/jcph.73","article-title":"Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis","volume":"53","author":"Rini","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clgc.2022.03.006_bib0005","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cpt.787","article-title":"Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology","volume":"102","author":"Verheijen","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"suppl 7","key":"10.1016\/j.clgc.2022.03.006_bib0006","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1200\/jco.2015.33.7_suppl.506","article-title":"Association of pharmacokinetics of axitinib with treatment outcome and adverse events in advanced renal cell carcinoma patients","author":"Tsuchiya","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.03.006_bib0007","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2022.03.006_bib0008","unstructured":"Common terminology criteria for adverse events Accessed from: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.html accessed date 18 Feb 2022."},{"key":"10.1016\/j.clgc.2022.03.006_bib0009","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00228-019-02704-2","article-title":"Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine","volume":"75","author":"Groenland","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clgc.2022.03.006_bib0010","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40262-014-0137-2","article-title":"Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets","volume":"53","author":"Yu","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clgc.2022.03.006_bib0011","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.clgc.2018.09.015","article-title":"Individualized dosing of axitinib based on first-dose area under the concentration-time curve for metastatic renal-cell carcinoma","volume":"17","author":"Miura","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2022.03.006_bib0012","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10637-015-0214-x","article-title":"Axitinib plasma pharmacokinetics and ethic differences","volume":"33","author":"Chen","year":"2015","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clgc.2022.03.006_bib0013","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00280-019-03862-x","article-title":"Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer","volume":"84","author":"Arasaratnam","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clgc.2022.03.006_bib0014","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2217\/fon-2017-0455","article-title":"Individualized dosing with axitinib: rationale and practical guidance","volume":"14","author":"Schmidinger","year":"2018","journal-title":"Future Oncol"},{"key":"10.1016\/j.clgc.2022.03.006_bib0015","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s10637-019-00743-1","article-title":"Axitinib pharmacologic therapeutic monitoring reveals severe under-exposure despite titration in patients with metastatic renal cell carcinoma","volume":"37","author":"Beinse","year":"2019","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clgc.2022.03.006_bib0016","article-title":"Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma","author":"Fukudo","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clgc.2022.03.006_bib0017","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3390\/jcm9051594","article-title":"Anti-angiogenesis and immunotherapy: novel paradigms to envision tailored approaches in renal cell-carcinoma","volume":"9","author":"Argentiero","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.clgc.2022.03.006_bib0018","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S1470-2045(13)70464-9","article-title":"Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial","volume":"14","author":"Rini","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2022.03.006_bib0019","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322000520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322000520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:34:56Z","timestamp":1761564896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767322000520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1558767322000520"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.03.006","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Axitinib Trough Concentration and its Influence on the Efficacy and Toxicity of Second-line Renal Cell Carcinoma Treatment","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}